Anthropic's Claude Enzyme Find Falls Short of CRISPR — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Anthropic announced on 23 September that its Claude model found "a novel enzyme system with CRISPR-like repeats" in bacteria-infecting viruses, dubbed array-associated reverse transcriptases (ART).
- Claude agents searched a large DNA database for reverse transcriptase proteins, flagging roughly 200,000 candidate sequences before one agent detected tandem repeats next to a reverse transcriptase gene.
- CRISPR itself was first spotted in E. coli in 1987 by Japanese researchers and named by Francisco Mojica; the breakthrough that enabled gene editing came in 2012 from Jennifer Doudna at UC Berkeley, earning a Nobel Prize in 2020.
- The article argues the Claude discovery is comparable in significance to that 1987 E. coli observation, not the 2012 breakthrough, and is dwarfed by DeepMind's AlphaFold as an AI contribution to biology.
- Existing gene-editing tools already include base editors and prime editors — which fuse a reverse transcriptase with Cas9 — plus bridge recombinases, meaning ART would at best add one more tool to the set.
- The finding requires substantial further research to determine whether the viral ART system enables gene editing that current tools cannot, which the article considers unlikely.
Why it matters: Anthropic's announcement was widely framed as a possible CRISPR-level breakthrough, but reverse transcriptases have already been adapted for gene editing in prime editors, and base editors plus bridge recombinases already populate the toolkit. The practical consequence: ART is at best one more candidate tool after extensive further lab work, and researchers — not the public — should judge whether this viral system offers capabilities existing tools lack.
Ask SkimNews
